Warts

Imiquimod 3.75% cream has recently been approved by both the FDA and Health Canada for the treatment of external genital warts. This article is an overview of EGW, phase 3 clinical trials leading to the approval of imiquimod 3.75% cream, and comparison with imiquimod 5% cream.

External genital warts (EGW) are a common infection caused primarily by human papillomavirus (HPV) types 6 and 11. This article discusses the pathogenesis of EGW, impact on patients, therapeutics, vaccination, and other topics.

External genital warts (EGW) are a common infection caused primarily by human papillomavirus (HPV) types 6 and 11. This article discusses the impact of EGW on the patient, co-factors for other STIs, and therapies for EGW.

Condylomata acuminata (genital or venereal warts) pose a significant health concern, especially amongst young adults. External genital warts (EGWs) are caused by infection with the human papillomavirus (HPV), the same virus that causes the majority of cervical cancers.

Imiquimod 5% cream (Aldara™, Graceway Pharmaceuticals) is an immune response modifier used for the topical treatment of anogenital warts in non-HIV-infected patients. Several randomized controlled trials have demonstrated that imiquimod 5% cream is a safe and efficacious treatment.

Condylomata acuminata (genital or venereal warts) pose a significant health concern, especially amongst young adults. Recent therapeutic advances such as topical immunomodulatory agents and a prophylactic vaccines have significantly broadened the options for management.

There are several new advances in treatments for warts, and specifically genital warts. Specific treatments and their mechanism of action are discussed.

Treatment will depend in part on the location, the age of the patient, as well as the size and immune status of the individual....

Human papillomavirus (HPV) is a very common sexually transmitted disease that is associated with a number of benign, premalignant, and frankly malignant lesions of the anogenital tract. Various treatments as well as new vaccines for HPV are discussed.

Most HPV infections are asymptomatic and can spontaneously clear on their own. However if treatment is required, there are a number of antiproliferative, destructive, immunomodulatory modalities available. Combination therapies have been shown to be advantageous.

HPV is a very common sexually transmitted disease that is associated with a number of benign, premalignant, and frankly malignant lesions of the anogenital tract. The majority of HPV infections are asymptomatic and are spontaneously cleared by a predominantly cell-mediated immune response.

HPV vaccines are highly immunogenic and have an excellent safety profile. HPV vaccines promise to offer an exciting contribution to healthcare and cancer prevention. However, many questions remain concerning who to vaccinate, the duration of protection, cost, public acceptance, and the potential for worldwide distribution.

Imiquimod (S-26308, R-837) (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4 amine), an immune response modifier, was approved as a 5% cream (Aldara, 3M Pharmaceuticals) by the US FDA in February 1997, for the treatment of genital and perianal warts.